Achieving Optimal Medical Therapy: Insights From the ORBITA Trial
Michael Foley(Imperial College Healthcare NHS Trust), Rasha Al‐Lamee(Imperial College Healthcare NHS Trust), Christopher Rajkumar(Imperial College Healthcare NHS Trust), Alexandra N. Nowbar(Barking, Havering And Redbridge University Hospitals NHS Trust), Matthew Shun‐Shin(Imperial College London), Ricardo Petraco(Imperial College London), Robert Gerber(East Sussex Healthcare NHS Trust), Sashiananthan Ganesananthan(Cardiff University), Kare Tang(Essex Cardiothoracic Centre), Sukhjinder Nijjer(Imperial College London), John R. Davies(St James's University Hospital), Iqbal Malik(Imperial College Healthcare NHS Trust), Thomas Keeble(Essex Cardiothoracic Centre), Peter O’Kane(Royal Bournemouth Hospital), James P. Howard(Lung Institute), Dárrel P. Francis(Lung Institute), Henry Seligman, Sayan Sen(Imperial College Healthcare NHS Trust), Andrew Sharp(University Hospital of Wales)
Cited by 17
Related Papers
Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial
|The Lancet|2017|1k
Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest
|New England Journal of Medicine|2021|979
Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction
|New England Journal of Medicine|2022|566
OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions
|New England Journal of Medicine|2023|341
A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina
|New England Journal of Medicine|2023|223